Alex G. Howarth has officially filed a Form 3 with the SEC, confirming his position as a director at Altimmune, Inc. This filing is significant as it underscores the leadership structure within the company, which operates in the pharmaceutical preparations sector.

Altimmune, Inc., based in Morristown, NJ, is a key player in the pharmaceutical preparations industry, focusing on innovative treatments and therapies. The company has undergone various name changes in its history, previously known as PharmAthene, Inc. and Healthcare Acquisition Corp. This filing, dated November 4, 2026, indicates that Howarth is actively engaged in the company's governance.

The Form 3 filing states that Howarth is a director of Altimmune, Inc. and was filed as of November 2, 2026. The document highlights his address as 350 Mount Kemble Avenue, Suite 1001, Morristown, NJ, and confirms his role in the company's leadership.

This update may affect stakeholders, including investors and employees, as it reflects the ongoing commitment of the board to provide effective governance and strategic direction for Altimmune. The pharmaceutical preparations industry is highly competitive, and leadership changes can influence company performance and investor confidence.

Details were not available in the SEC filing regarding any upcoming actions or decisions following this filing. However, the continued involvement of directors like Howarth is crucial for the company's future endeavors.